Two Sigma Advisers’s Artelo Biosciences ARTL Stock Holding History

Two Sigma Advisers’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-127	Closed	-$40.9K	–	2382
2023 Q2	$40.9K	Sell	127 -41	-24%	-$13.5K	﹤0.01%	2284
2023 Q1	$63.2K	Sell	168 -54	-24%	-$24.6K	﹤0.01%	2428
2022 Q4	$104K	Buy	222 +6	+3%	+$2.82K	﹤0.01%	2292
2022 Q3	$121K	Buy	+216	New	+$157K	﹤0.01%	2281
2022 Q1	–	Sell	-7	Closed	-$8K	–	2726
2021 Q4	$8K	Sell	7 -8	-53%	-$14.2K	﹤0.01%	2578
2021 Q3	$28K	Sell	15 -92	-86%	-$210K	﹤0.01%	2396
2021 Q2	$309K	Buy	+107	New	+$329K	﹤0.01%	2132

Other funds holding ARTL

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Advisers's ARTL Position: Q3 2023 in Review

Two Sigma Advisers sold out of Artelo Biosciences (ARTL) in Q3 2023, closing a stake of 127 shares — an estimated $40.9K sold.

Two Sigma Advisers first reported a position in ARTL in Q2 2021 and held it in 7 quarters. The position peaked at $309K in Q2 2021. 4 funds tracked by Wall St. Rank hold ARTL as of Q3 2023.

Two Sigma Advisers reported no remaining Artelo Biosciences position as of Q3 2023 after selling out during the quarter.
Two Sigma Advisers sold 127 Artelo Biosciences shares in Q3 2023, an estimated $40.9K.
Two Sigma Advisers first reported a position in Artelo Biosciences in Q2 2021 and held it in 7 quarters.
Two Sigma Advisers's Artelo Biosciences position peaked at $309K in Q2 2021.
4 funds tracked by Wall St. Rank held Artelo Biosciences as of Q3 2023.

Based on Two Sigma Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.